Winship Cancer Institute

Emory University

Atlanta, GA

Accepting patients

EXCALIBER RRMM

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

DREAMM5

Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Learn more
  • Antibody Drug Conjugate (ADC)
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 2
  • Has results

Accepting patients

MonumenTAL-1

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 2

Accepting patients

Daratumumab for Patients with Kidney Failure

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2

Accepting patients

CFT7455

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more
  • Phase 1/2

Not yet accepting

SUCCESSOR-2

Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

Personalized Autologous Transplant

Personalized Autologous Transplant for Multiple Myeloma
Learn more
  • Autologous Stem Cell Transplant
  • Vaccine
  • Phase 1

Not yet accepting

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Not yet accepting

MagnetisMM-7

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 3
6 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase